Inhibitor of human C1-esterase (Inhibitor of human C1-esterase)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Bradykinin receptor antagonists

Included in the formulation
  • Berinert®
    lyophilizate in / in 
    CESEL Behring GmbH     Germany
    • АТХ:

    B.06.A.C.01   C1-inhibitor based on plasma

    Pharmacodynamics:

    It blocks the pathway of the complement system by inactivating the enzymatically active components C1s and C1r, forming complexes in a stoichiometric structure of 1: 1. Inhibits the blood coagulation factor XIIa. Also inhibits plasma kallikrein.

    Pharmacokinetics:

    After intravenous administration, the maximum concentration in the blood plasma is reached after 7-10 minutes.

    The half-life is 36 hours. In children, the half-life is 33 hours.

    Indications:

    It is used to treat acute attacks with hereditary angioedema edema of types I and II.

    ICD-10

    III.D80-D89.D84.1   Defect in the complement system

    Contraindications:

    Individual intolerance, children under 2 years old.

    Carefully:

    Propensity to allergic reactions.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used for life indications.

    Dosing and Administration:

    Intravenously slow to 20 IU / kg.

    The highest daily dose: 20 IU / kg.

    The highest single dose: 20 IU / kg.

    Side effects:

    The cardiovascular system: rarely - tachycardia, hot flashes, hypertension, development of thrombosis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Not described.

    Special instructions:

    With the tendency of patients to allergic reactions, it is recommended to premedicate with glucocorticosteroids and antihistamines before administration of the drug.

    Instructions
    Up